Finance
Biotechnology firm Galapagos receives offers for cell therapy business
Published by Global Banking & Finance Review®
Posted on October 1, 2025
1 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on October 1, 2025
1 min readLast updated: January 21, 2026
Galapagos has received offers for its cell therapy business and will decide on a sale by November 5. The company is also planning a spinoff of its innovative medicines by 2025.
(Reuters) -Biotechnology firm Galapagos' board has received non-binding offers from several groups, mainly comprised of financial investors, for its cell therapy business, which it began mulling options for in May, the Amsterdam-listed group said on Wednesday.
The company said its board will evaluate options, including a sale or divestment of its cell therapy business, depending on other offers it may receive, with a decision expected by November 5.
Galapagos, which has a market capitalisation of 1.97 billion euros ($2.31 billion), according to data compiled by LSEG, said in May it would reassess its planned split of its innovative medicines business due to unfavourable regulatory and market conditions.
In January, the pharmaceutical firm had said that it expected the spinoff of its innovative medicines business to take effect by mid-2025, which would have given the firm a 2.45 billion euro influx of cash.
($1 = 0.8527 euros)
(Reporting by Chandni Shah in Bengaluru; Editing by Alan Barona)
Market capitalisation is the total market value of a company's outstanding shares of stock, calculated by multiplying the share price by the total number of shares.
Financial investors are individuals or institutions that allocate capital to various financial assets with the expectation of generating a return.
An investment offer is a proposal made by an entity to potential investors, outlining the terms and conditions for investing in a business or project.
Explore more articles in the Finance category
